CoChat
Sign Up
Cited by 254

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

Drug-induced Liver Injury (DILI) Study Group, Yu, Yue-cheng, Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Yi-min, Chen, Cheng-wei, Chen, Jin-jun, Chen, Jun, Cong, Wen-ming, Ding, Yang, Duan, Zhong-ping, Fu, Qing-chun, Guo, Xiao-yan, Hu, Peng, Hu, Xi-qi, Jia, Ji-dong, Lai, Rong-tao, Li, Dong-liang, Liu, Ying-xia, Lu, Lun-gen, Ma, Shi-wu, Ma, Xiong, Nan, Yue-min, Ren, Hong, Shen, Tao, Wang, Hao, Wang, Ji-yao, Wang, Tai-ling, Wang, Xiao-jin, Wei, Lai, Xie, Qing, Xie, Wen, Yang, Chang-qing, Yang, Dong-liang, Yu, Yan-yan, Zeng, Min-de, Zhang, Li, Zhao, Xin-yan, Zhuang, Hui·2017·Hepatology International
DOI 10.1007/s12072-017-9793-2PMC PMC5419998
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12072-017-9793-2

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 134

  1. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68 · DOI · Paper page
  2. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guide: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966 · DOI · Paper page
  3. Devarbhavi H. An update on drug—induced liver injury. J Clin Exp Hepatol. 2012;2(3):247–259 · DOI
  4. Hillman L, Gottfried M, Whitsett M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111(7):958–965 · DOI
  5. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934 · DOI · Paper page
  6. Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21(11):1139–1154 · DOI
  7. Li L, Jiang W, Wang JY. Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China. 2007;1(1):58–61 · DOI
  8. Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57(3):873–874 · DOI
  9. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–155 · DOI
  10. Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–122 · DOI
  11. Lai RT, Wang H, Gui HL, et al. Clinical and pathological features in 138 cases of drug-induced liver injury. Chin J Hepatol 2012;20(3):185–189 (article in Chinese)
  12. Hao KY, Yu YC, He CL, et al. Analysis on the diagnosis, clinical features and prognosis of 140 cases with drug-induced liver injury based on the RUCAM scales. Chin J Hepatol 2014;22(12):82–85 (article in Chinese)
  13. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–1023 · DOI · Paper page
  14. Bjornsson E, Jerlstad P, Bergqvist A, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–1101 · DOI · Paper page
  15. Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem Biophys. 2012;64(2):77–83 · DOI
  16. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7(7):875–890 · DOI
  17. Hoofnagle JH, Navarro VJ. Drug-induced liver injury: Icelandic lessons. Gastroenterology. 2013;144(7):1335–1336 · DOI
  18. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001–2009 · DOI · Paper page
  19. Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol. 2007;47(4):514–520 · DOI
  20. Azizi F, Amouzegar A. Management of hyperthyroidism during pregnancy and lactation. Eur J Endocrinol. 2011;164:871–876 · DOI
  21. Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(2):369–376 · DOI
  22. Saadi T, Waterman M, Yassin H, et al. Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. Int J Gen Med. 2013;6:703–706 · DOI
  23. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22(1):1–13 · DOI
  24. Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis. 2014;18(1):165–178 · DOI
  25. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581–1588 · DOI · Paper page
  26. Sharma SK1, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166(7):916–919 · DOI
  27. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 2007;11(1):78–84
  28. Mitchell JR, Long MW, Thorgeirsson UP, et al. Acetylation rates and monthly liverfunction tests during one year of isoniazid preventive therapy. Chest. 1975;68(2):181–190 · DOI
  29. Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 1999;29(2):451–463 · DOI
  30. Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011;26:338–341 · DOI
  31. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53(4):1377–1387 · DOI
  32. Khandelwal N, James LP, Sanders C, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011;53(2):567–576 · DOI
  33. Guengerich FP. Cytochrome P450 Activation of Toxins and Hepatotoxicity. In Kaplowitz N, DeLeve LD. Drug Induced Liver Disease, 3rd ed. New York: Elsevier; 2013. 15–33 · DOI
  34. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116–126 · DOI
  35. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology. 2010;52(2):748–761 · DOI
  36. Wei CY, Lee MTM, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet. 2012;21(R1):R58–R65 · DOI
  37. Alfirevic A, Gonzalez-Galarza F, Bell C, et al. In silico analysis of HLA associations with drug-induced liver injury use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012;4(6):51 · DOI
  38. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenom J. 2008;8(3):186–195 · DOI
  39. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature. 2010;42(8):711–714
  40. Goncalves RL, Rothschild DE, Quinlan CL, et al. Sources of superoxide/H2O2 during mitochondrial proline oxidation. Redox Biol. 2014;2:901–909 · DOI
  41. Choumar A, Tarhuni A, Letteron P, et al. Lipopolysaccharide-induced mitochondrial DNA depletion. Antioxid Redox Signal. 2011;15:2837–2854 · DOI
  42. Kim JS, He L, Qian T, et al. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. Curr Mol Med. 2003;3(6):527–535 · DOI
  43. Nakagawa H, Maeda S, Hikiba Y, et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology. 2008;135:1311–1321 · DOI
  44. Jaeschke H, McGill MR, Williams CD, et al. Current issues with acetaminophen hepatotoxicity—a clinically relevant model to test the efficacy of natural products. Life Sci. 2011;88(17–18):737–745 · DOI
  45. Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen induced liver injury in mice. Toxicol Lett 2010;192(3):387–394 · DOI
  46. Janssens S, Pulendran B, Lambrecht BN. Emerging functions of the unfolded protein response in immunity. Nat Immunol. 2014;15(10):910–919 · DOI
  47. Dara L, Ji C, Neil Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology. 2011;55(5):1752–1763 · DOI
  48. Fredriksson L, Wink S, Herpers B, et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci. 2014;140(1):144–159 · DOI
  49. Lai R, Xiang X, Mo R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015;63(1):148–155 · DOI
  50. Masson MJ, Collins LA, Pohl LR. The role of cytokines in the mechanism of adverse drug reactions. Handb Exp Pharmacol. 2010;196:195–231 · DOI
  51. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009;29(4):383–392 · DOI
  52. Ke PY, Chen SS. Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses 2012;4(10):2251–2290 · DOI
  53. Henkel A, Green RM. The unfolded protein response in fatty liver disease. Semin Liver Dis. 2013;33(4):321–329 · DOI
  54. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914–928 · DOI
  55. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf. 2014;13(1):67–81 · DOI
  56. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012;44(1):107–115 · DOI
  57. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–976 · DOI · Paper page
  58. Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vsp34 that mediates ROS-induced autophagy downstream of DAPk. Cell Death Differ 2012;19:788–797 · DOI
  59. Ding WX, Manley S, Ni HM. The emerging role of autophagy in alcoholic liver disease. Exp Biol Med. 2011;236:546–556 · DOI
  60. Roth RA, Ganey PE. Role of inflammation in drug-induced liver injury. In: Kaplowitz N, Deleve LD, editors. Drug-Induced Liver Disease. 3rd ed. San Diego: Academic Press; 2013. 157–173 · DOI
  61. Wu MH, Zang P, Huang X. Toll-like receptors in innate immunity and infectious diseases. Front Med China. 2010;4(4):385–393 · DOI
  62. Hansen JD, Vojtech LN, Laing KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol. 2011;35(9):886–897 · DOI
  63. Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol. 2005;33(1):41–51 · DOI
  64. Kleiner DE. Histopathological Evaluation of Drug-Induced Liver Disease. In Kaplowttz N, DeLeve LD, ed. Drug-induced Liver Disease, 3rd ed. New York, Academic Press; 2013. 241–261 · DOI
  65. Goodman ZD. Drug hepatotosicity. Clin Liver Dis. 2002;6(2):381–397 · DOI
  66. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–492 · DOI
  67. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364–372 · DOI
  68. Tang W. Drug metabolite profiling and elucidation of drug induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2007;3(3):407–420 · DOI
  69. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–144 · DOI
  70. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129(2):512–521 · DOI · Paper page
  71. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730–742 · DOI
  72. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108 · DOI · Paper page
  73. Robles-Diaz M, Lucena MI, Kaplowitz N, et al; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-Based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147(1):109–118 · DOI · Paper page
  74. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95–106 · DOI · Paper page
  75. Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012;13(1):33–39 · DOI · Paper page
  76. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4(4):332–346 · DOI
  77. Kootte AM, Siegel AM, Koorenhof M. Generalised peliosis hepatis mimicking metastases after long-term use of oral contraceptives. Neth J Med. 2015;73(1):41–43
  78. Yu CY, Chang LC, Chen LW, et al. Peliosis hepatis complicated by portal hypertension following renal transplantation. World J Gastroenterol. 2014;20(9):2420–2425 · DOI
  79. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–1384 · DOI
  80. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011;(3)34:243–252 · DOI
  81. Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60(5):1063–1074 · DOI
  82. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):1680–1689 · DOI
  83. Fannin RD, Russo M, O’Connell TM, et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology. 2010;51(1):227–236 · DOI
  84. Su YW, Chen X, Jiang ZZ, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One. 2012;7(5):e37395 · DOI
  85. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012;56(5):1946–1957 · DOI
  86. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777–787 · DOI
  87. Watkins PB. Biomarkers for drug-induced liver injury. In: Kaplowitz N, Deleve LD, editors. Drug-Induced Liver Disease. 3rd ed. San Diego: Academic Press; 2013. 275–286. · DOI
  88. Kenna JG. Current concepts in drug-induced bile salt export pump (BSEP) interference. Curr Protoc Toxicol 2014;61:23.7.1–23.7.15 · DOI
  89. Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;4(4):286–292 · DOI
  90. Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54(4):666–673 · DOI · Paper page
  91. Vuppalanchi R, iangpunsakul S, Chalsani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States. Am J Gastroenterol 2007;102(3):558–562 · DOI
  92. Loras C, Gisber JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59(10):1340–1346 · DOI
  93. Makar GA, Weiner MG, Kimmel SE, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008;17(1):43–51 · DOI
  94. Aithal GP, Watkins PB, Andrade RJ. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815 · DOI · Paper page
  95. Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330 · DOI · Paper page
  96. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14–46 · DOI · Paper page
  97. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology. 1997;26(3):664–669 · DOI · Paper page
  98. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–130 · DOI · Paper page
  99. García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27(9):780–789 · DOI · Paper page
  100. . 2005;46(2):85–90 (articles in Japanese). · DOI
  101. Hepatobiliary Diseases Cooperation Group of CSG. Recommendations for the diagnosis and treatment of acute drug-induced liver injury (draft). Chin J Dig 2007;27(11):765–767 (articles in Chinese).
  102. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel–Uclaf causality assessment method. Hepatology. 2010;51(6):2117–2126 · DOI · Paper page
  103. Research Group of Liver Failure and Artificial Liver; Society of Infectious Disease (SID); Chinese Medical Association (CMA); Research Group of Severe Liver Disease and Artificial Liver; Chinese Society of Hepatology (CSH); CMA. Guidelines for diagnosis and treatment of liver failure (2012 edition). Chin J Hepatol 2013;21(3):178–179 (articles in Chinese).
  104. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the study of liver diseases position paper on acute liver failure 2011. Hepatology. 2012;55(3):965–967 · DOI
  105. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009;7(10):1130–1137 · DOI
  106. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–939 · DOI · Paper page
  107. Miao Q, Bian Z, Tang R, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol. 2015;48(2–3):226–235 · DOI
  108. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–2048 · DOI · Paper page
  109. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–739 · DOI · Paper page
  110. Wu S, Xia Y, Lv X, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a largecohort of Chinese patients. J Gastroenterol Hepatol. 2015;30(3):540–545 · DOI
  111. Ford R, Schwartz L, Dancey J, US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), et al. Guidance for industry: drug-induced liver injury—premarketing clinical evaluation. Eur J Cancer. 2009;45(2):268–274 · DOI
  112. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285–292 · DOI
  113. Masubuchi Y, Nakayama J, Sadakata Y. Protective effects of exogenous glutathione and related thiol compounds against drug-induced liver injury. Biol Pharm Bull. 2011;34(3):366–370 · DOI
  114. Zwingmann C, Bilodeau M. Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver. Hepatology. 2006;43(3):454–463 · DOI
  115. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–864 · DOI · Paper page
  116. Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomized controlled trial. Lancet. 2014;383(9918):697–704 · DOI
  117. Singh S, Hynan LS, Lee WM, Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58(5):1397–1402 · DOI
  118. Mao YM, Zeng MD, Chen Y, et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study. Chin J Hepatol 2009;17(11):847–851 (article in Chinese)
  119. Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–914 · DOI
  120. Chu NH, Li L, Zhang X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–480 · DOI
  121. Zhang QH, Shi GF, Li Q. Effects of diammonium glycyrrhizinate enteric-coated capsule in the treatment of 2396 cases with chronic hepatitis. Chin J Infect Dis 2007;25(3):175–176 (article in Chinese)
  122. Abenavoli L, Capasso R, Milic N, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–1432 · DOI
  123. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006;10(2):207–217 · DOI
  124. Ni LD, Xie Q, Li HW, et al. Ursodeoxycholic acid in the treatment of drug-injury: an open controlled clinical trial. Chin Hepatol 2009;14(4):278–280 (article in Chinese)
  125. Zhao P, Duan GF, Du L, et al. Systematic evaluation on the efficacy of ademetionine in patients of drug-induced liver injury. Chin J Gastroenterol Hepatol 2011;20(4):341–344 (article in Chinese)
  126. Mato JM, Lu SC. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology. 2007;45(5):1306–1312 · DOI
  127. Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345–349 · DOI
  128. Jeong R, Lee YS, Sohn C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. Scand J Gastroenterol. 2015;50(4):439–446 · DOI
  129. Yu YC, Chen CW. Interpretation of ACG clinical guidelines for the diagnosis and treatment of idiosyncratic drug-induced liver injury. Chin Hepatol 2014;19(8):570–574 (article in Chinese)
  130. Zhang L, Yang XH. Phamacovigilance concept should be introduced sufficiently into the process of safety monitoring and evaluation of Chinese traditional medicine. Chin J Integr Tradit Western Med 2009;29(9):863–866 (article in Chinese)
  131. Zhang L, Wong LY, He Y, Wong IC. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37(10):765–770 · DOI
  132. Graham DJ, Mosholder AD, Gelperin K, et al. Pharmacoepidemiology and risk management. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. West Sussex: Wiley; 2005. 51530.
  133. Olson S, Robinson S, Giffin R; Institute of Medicine. Accelerating the development of biomarkers for drug safety: workshop summary. National Academies Press. Ibid. Watkins PB, Bloom J, Hunt C. Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials, Chap 5. 2009. 4257
  134. Willy M, Li Z. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA-approved product labeling. Pharmacoepidemiol Drug Saf. 2004;13(4):201–206 · DOI

Cited by

Sorted by citations

Metadata

Authors
Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., Duan, Z.-P., Fu, Q.-C., Guo, X.-Y., Hu, P., Hu, X.-Q., Jia, J.-D., Lai, R.-T., Li, D.-L., Liu, Y.-X., Lu, L.-G., Ma, S.-W., Ma, X., Nan, Y.-M., Ren, H., Shen, T., Wang, H., Wang, J.-Y., Wang, T.-L., Wang, X.-J., Wei, L., Xie, Q., Xie, W., Yang, C.-Q., Yang, D.-L., Yu, Y.-Y., Zeng, M.-D., Zhang, L., Zhao, X.-Y., & Zhuang, H.
ORCID
Yu, Yue-cheng
Venue
Hepatology International
Publisher
Springer Science and Business Media LLC
Published
2017-04-12
Volume
11
Issue
3
Pages
221-241
ISSN
  • 1936-0533
  • 1936-0541
DOI
10.1007/s12072-017-9793-2
PMC
PMC5419998
Cited by
254
References
10
Language
en
Licence
creativecommons.org/licenses/by/4.0 (unspecified)
Funders
Science and Technology Department of People's Republic of China (No. 2012ZX09303-001)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review